China’s obesity drug makers take on global giants as Novo Nordisk patent expires
Analysis Summary
- Propaganda Score
- 0% (confidence: 95%)
- Summary
- The article reports that China's pharmaceutical companies are poised to compete with global giants like Novo Nordisk in the weight-loss drug market following the expiration of patent protections for semaglutide. It highlights trial results from Hengrui Medicine and Innovent Biologics showing their drugs achieved higher weight loss rates than semaglutide in clinical trials.
Fact-Check Results
“Novo Nordisk’s blockbuster semaglutide, which generated about US$35 billion in global revenue last year, lost patent protection in China on March 20”
❓
INSUFFICIENT EVIDENCE
— No evidence found in archive to confirm patent expiration date or revenue figures
“Notable applicants included Hengrui Medicine, China’s largest listed pharmaceutical firm by revenue, and Innovent Biologics, whose lower-dose version of mazdutide became the first home-grown obesity drug approved in China for chronic weight management”
❓
INSUFFICIENT EVIDENCE
— No evidence found in archive to verify applicants or drug approval status
“Both Hengrui Pharma’s ribupatide and Innovent’s higher-dose mazdutide have reported phase 3 trial data suggesting greater weight-loss efficacy than semaglutide”
❓
INSUFFICIENT EVIDENCE
— No evidence found in archive to assess trial data comparisons
“Hengrui’s once-weekly injection delivered 17.7 per cent average weight loss at its highest dose of 6 milligrams at 48 weeks, while Innovent’s 9mg of mazdutide achieved an 18.55 per cent average weight reduction at week 60”
❓
INSUFFICIENT EVIDENCE
— No evidence found in archive to verify specific weight loss statistics